Company intelligence / Profile preview
TauC3 Biologics
Stevenage, United Kingdom
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
TauC3 Biologics' lead candidate TBL-100 is a potent, humanized monoclonal antibody targeting tauC3, with picomolar affinity and high specificity, aimed at the treatment of Alzheimer's disease and progressive supranuclear palsy. It has demonstrated the ability to block tau propagation in preclinical models[1][3][5][6].
- Therapeutic areas
- Neurology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
LifeArc
Beyond the preview
Go deeper on TauC3 Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TauC3 Biologics.